Projected Estimates of Opioid Mortality After Community-Level Interventions.
Computer Simulation
Decision Support Techniques
Humans
Massachusetts
Naloxone
/ supply & distribution
Narcotic Antagonists
/ supply & distribution
Opiate Overdose
/ mortality
Opiate Substitution Treatment
/ statistics & numerical data
Retention in Care
/ statistics & numerical data
Rural Population
Urban Population
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
entrez:
15
2
2021
pubmed:
16
2
2021
medline:
13
4
2021
Statut:
epublish
Résumé
The United States is experiencing a crisis of opioid overdose. In response, the US Department of Health and Human Services has defined a goal to reduce overdose mortality by 40% by 2022. To identify specific combinations of 3 interventions (initiating more people to medications for opioid use disorder [MOUD], increasing 6-month retention with MOUD, and increasing naloxone distribution) associated with at least a 40% reduction in opioid overdose in simulated populations. This decision analytical model used a dynamic population-level state-transition model to project outcomes over a 2-year horizon. Each intervention scenario was compared with the counterfactual of no intervention in simulated urban and rural communities in Massachusetts. Simulation modeling was used to determine the associations of community-level interventions with opioid overdose rates. The 3 examined interventions were initiation of more people to MOUD, increasing individuals' retention with MOUD, and increasing distribution of naloxone. Data were analyzed from July to November 2020. Reduction in overdose mortality, medication treatment capacity needs, and naloxone needs. No single intervention was associated with a 40% reduction in overdose mortality in the simulated communities. Reaching this goal required use of MOUD and naloxone. Achieving a 40% reduction required that 10% to 15% of the estimated OUD population not already receiving MOUD initiate MOUD every month, with 45% to 60%% retention for at least 6 months, and increased naloxone distribution. In all feasible settings and scenarios, attaining a 40% reduction in overdose mortality required that in every month, at least 10% of the population with OUD who were not currently receiving treatment initiate an MOUD. In this modeling study, only communities with increased capacity for treating with MOUD and increased MOUD retention experienced a 40% decrease in overdose mortality. These findings could provide a framework for developing community-level interventions to reduce opioid overdose death.
Identifiants
pubmed: 33587136
pii: 2776442
doi: 10.1001/jamanetworkopen.2020.37259
pmc: PMC7885041
doi:
Substances chimiques
Narcotic Antagonists
0
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2037259Subventions
Organisme : NIDA NIH HHS
ID : R01 DA046527
Pays : United States
Organisme : NIDA NIH HHS
ID : K01 DA051684
Pays : United States
Organisme : NIDA NIH HHS
ID : P30 DA040500
Pays : United States
Organisme : NIDA NIH HHS
ID : DP2 DA051864
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI042853
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Addict Sci Clin Pract. 2017 Feb 28;12(1):7
pubmed: 28245872
JAMA Netw Open. 2020 Feb 5;3(2):e1920622
pubmed: 32022884
J Subst Abuse Treat. 2018 Feb;85:90-96
pubmed: 28733097
Addiction. 2016 May;111(5):883-91
pubmed: 26642424
Lancet. 2018 Jan 27;391(10118):309-318
pubmed: 29150198
Drug Alcohol Depend. 2014 Jul 1;140:69-77
pubmed: 24837584
JAMA Netw Open. 2020 Apr 1;3(4):e203711
pubmed: 32320038
Lancet Public Health. 2018 May;3(5):e218-e225
pubmed: 29678561
JAMA Netw Open. 2019 Jun 5;2(6):e196373
pubmed: 31251376
J Subst Abuse Treat. 2003 Dec;25(4):279-85
pubmed: 14693257
Health Serv Res. 2019 Apr;54(2):390-398
pubmed: 30665272
BMJ. 2013 Jan 30;346:f174
pubmed: 23372174
Ann Fam Med. 2019 May;17(3):212-220
pubmed: 31085525
Am J Public Health. 2018 Dec;108(12):1675-1681
pubmed: 30359112
Drug Alcohol Depend. 2006 Jun 28;83(2):147-56
pubmed: 16364568
Contemp Clin Trials. 2019 Jan;76:93-103
pubmed: 30508592
Addiction. 2020 Aug;115(8):1494-1495
pubmed: 32144943
Addiction. 2019 Sep;114(9):1602-1613
pubmed: 31166621
Int J Neuropsychopharmacol. 2008 Aug;11(5):641-53
pubmed: 18205978
Addiction. 2006 Nov;101(11):1546-60
pubmed: 17034434
Drug Alcohol Depend. 2013 Feb 1;128(1-2):71-6
pubmed: 22921476
Addiction. 2016 Jul;111(7):1177-87
pubmed: 27028542
J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):493-503
pubmed: 16652059
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Ann Intern Med. 2018 Aug 7;169(3):137-145
pubmed: 29913516
Addiction. 2007 Dec;102(12):1954-9
pubmed: 18031430
Addiction. 2017 Mar;112(3):502-515
pubmed: 27776382
Subst Abus. 2012;33(1):9-18
pubmed: 22263709
Focus (Am Psychiatr Publ). 2019 Apr;17(2):128-133
pubmed: 31975968
Am J Public Health. 2018 May;108(5):642-648
pubmed: 29565661
NCHS Data Brief. 2020 Jan;(356):1-8
pubmed: 32487285
Addiction. 2020 Aug;115(8):1496-1508
pubmed: 32096908